

**IMPORTANT: THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF IN DOUBT, PLEASE SEEK PROFESSIONAL ADVICE.**

Each of The Stock Exchange of Hong Kong Limited (“**SEHK**”), Hong Kong Exchanges and Clearing Limited (“**HKEx**”), Hong Kong Securities Clearing Company Limited and the Securities and Futures Commission (the “**SFC**”) takes no responsibility for the contents of this Announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Announcement.

The Manager accepts full responsibility for the accuracy of the information contained in this Announcement as at the date of publication, and confirms, having made all reasonable enquiries, that to the best of its knowledge and belief, as at the date of publication, opinions expressed in this Announcement have been arrived at after due and careful consideration.

SFC authorisation is not a recommendation or an endorsement of a scheme nor does it guarantee the commercial merits of a scheme or its performance. It does not mean the scheme is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.

## **ChinaAMC Global ETF Series (the “Trust”)**

*(a Hong Kong umbrella unit trust, authorised under  
Section 104 of the Securities and Futures Ordinance (Cap. 571) of Hong Kong)*

## **ChinaAMC Hang Seng Hong Kong Biotech Index ETF**

*HKD counter Stock Code: 03069*

*USD counter Stock Code: 09069*

**(the “Sub-Fund”)**

## **Announcement Change of Index Methodology**

Unless otherwise stated, capitalized terms in this Announcement have the same meanings as defined in the prospectus of the Trust and the Sub-Fund dated 8 November 2021.

China Asset Management (Hong Kong) Limited (the “**Manager**”), the manager of the Trust and the Sub-Fund, hereby wishes to inform Unitholders that Hang Seng Indexes Company Limited (the “**Index Provider**”), being the index provider of Hang Seng Hong Kong-Listed Biotech Index (the “**Index**”), which is the underlying index of the Sub-Fund, has introduced certain changes to the methodology of the Index which has been applied in the index review for the period ended 31 March 2023. The corresponding constituent changes will take effect from 5 June 2023.

Changes to the Index will be as follow:

	<b>Existing rules</b>	<b>New rules</b>
Listing history requirement	There is no listing history requirement for the universe of stocks of the Index.	The universe of stocks for the Index consist of Main Board listed securities on the SEHK that have at least one month trading history.
Weighting	The Index is a free float adjusted market capitalisation weighted index with a 10% cap on individual stocks.	The Index is a free float adjusted market capitalisation weighted index with a 10% cap on individual stocks. The free float adjusted market capitalisation of individual stocks mainly engaged in pharmaceuticals distribution will be discounted by 50% in the weighting calculation.
Turnover requirement	Securities with 3 months average daily trading turnover over HKD 5 million are eligible.	A security is regarded as passing the monthly turnover test if it attains a minimum velocity of 0.1% in that month (details of velocity test is as described in the Index Methodology General Guide published by the Index Provider).
Constituent selection	<p>The Market value (“MV”) of each individual security refers to the average of the month-end MVs of the past 12 months (“12-month-average MV”) of any review period. Securities in the Universe are sorted in descending order of MV and the cumulative MV coverage is calculated at each security.</p> <p>Securities among those that constitute the cumulative MV coverage of top 95% will be included as constituents of the Index.</p>	The securities with the top 50 highest market value rank will be included as constituents of the Index.
Number of constituent securities	The number of constituent securities is variable and there should be at least 30 constituents.	The number of constituent securities is capped at 50.
Buffer zone	Existing constituents ranked below the top 96% of the cumulative market value coverage of the Universe will be removed from the Index while non-constituent stocks ranked within the top 94% will be included.	Existing constituents ranked lower than 60 <sup>th</sup> in terms of the market value rank of the Universe will be removed from the Index while non-constituent stocks ranked 40 <sup>th</sup> or above will be included.
Fast entry	Fast entry is not applicable.	To qualify as a fast entry, a newly listed security must after the close of

		business on its first trading day, have a full market capitalisation rank within the top five of the existing constituents. The security will be included in the Index after the close of business on the tenth day of trading.
Replacement for Ad-hoc Removal	No.	Yes, the outgoing constituent securities will be replaced by the highest ranked candidate from last regular review.

The portfolio of the Sub-Fund will be rebalanced on or around 5 June 2023 to reflect the changes to the Index constituents (if any) as a result of the above changes.

For the avoidance of doubt, there are no changes to the Index methodology other than as set out above. The investment strategy and risk profile of the Sub-Fund do not change. The Manager believes that (i) the changes do not amount to a material change to the Sub-Fund; (ii) there will not be any material change or increase in the overall risk profile of the Sub-Fund following the above changes; and (iii) the changes do not have a material adverse impact on holders' rights or interests (including changes that may limit holders' ability in exercising their rights).

For further details, please refer to the announcement dated 31 March 2023 issued by the Index Provider which is available at <https://www.hsi.com.hk/static/uploads/contents/en/news/indexChgNotice/20230331T163059.pdf> (this website has not been reviewed by the SFC).

The prospectus is updated to reflect the above changes by way of an addendum. The addendum and the revised product key facts statement of the Sub-Fund reflecting the above changes is made available on the Manager's website at <http://www.chinaamc.com.hk/> (this website has not been reviewed by the SFC) and HKEx's website at [www.hkex.com.hk](http://www.hkex.com.hk).

Investors who have any enquiries regarding the above may contact the Manager at 37th Floor, Bank of China Tower, 1 Garden Road, Central, Hong Kong or our enquiry hotline at (852) 3406 8686 during office hours.

**China Asset Management (Hong Kong) Limited  
as Manager of the Trust and the Sub-Fund  
19 May 2023**